Form 4: Predictive Oncology Director Granted 64,680 RSUs

Predictive Oncology Inc. Director Veena Rao was granted 64,680 restricted stock units, vesting in full on October 31, 2025.

Summary

• Director Veena Rao of Predictive Oncology Inc. (POAI) was granted 64,680 restricted stock units (RSUs) on September 9, 2025.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs will vest in full on October 31, 2025, contingent upon continued service through the vesting date.
• Following this transaction, Veena Rao beneficially owns a total of 73,797 shares of common stock.
• The transaction was reported as an acquisition (A) with a price of $0.00 per unit, indicating a grant rather than a purchase.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning interests but not a significant operational or financial announcement that would drastically alter the company's outlook.

Positives

• The grant of restricted stock units aligns the director's financial interests with the long-term performance and shareholder value of Predictive Oncology Inc.

Future Outlook

The granted restricted stock units are scheduled to vest in full on October 31, 2025, contingent on the director's continued service.

Industry Context

The grant of equity compensation, such as restricted stock units, to directors is a common practice across various industries. It serves to incentivize long-term commitment and align the interests of board members with those of shareholders, particularly in the biotechnology and healthcare sectors where long-term strategic development is crucial.

Comparison to Industry Standards

• Equity grants to directors, like the RSUs provided to Veena Rao, are a standard component of compensation packages in publicly traded companies, including those in the oncology and predictive medicine space.
• This practice is consistent with corporate governance best practices aimed at fostering alignment between leadership and shareholder interests, similar to compensation structures observed at companies like Guardant Health (GH) or Exact Sciences (EXAS) for their non-executive directors.

Related Party Transactions

• The grant of restricted stock units to Director Veena Rao constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 64,680 restricted stock units are expected to vest in full on October 31, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to an existing director, which is a standard compensation practice and does not provide new information significant enough to alter an investment recommendation based solely on this disclosure. It reinforces alignment of interests but does not indicate a material change in the company's operational or financial trajectory.

Keywords

Predictive Oncology, POAI, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant